Lung function test used to diagnose COPD can aid patients whilst reducing healthcare costs

According to a recent study by the Canadian Medical Association Journal (CMAJ), patients with chronic obstructive pulmonary disease (COPD) would benefit greatly if pulmonary function testing was used more consistently when diagnosing the condition. COPD is currently the third principal cause of death worldwide and affects over 10% of adults. At the moment, testing airflow

Continue Reading

New EU study highlights differing priorities in physician’s therapy goals when treating advanced lung cancer patients

Results from a survey analysing the prescribing behaviour of 500 European physicians treating patients with advanced non-small cell lung cancer (NSCLC) have been published in Clinical Lung Cancer. The research examined the primary therapy goal of physicians and their choice of treatment for patients with advanced adenocarcinoma of the lung, after first-line chemotherapy. An overview

Continue Reading

NICE publish recommendation of hypophosphatasia drug

NICE has published further draft guidance as part of its highly specialised technologies programme recommending asfotase alfa (Strensiq, Alexion Pharma UK) for children with hypophosphatasia. A rare, and often fatal genetic condition. The drug is the first treatment to target the underlying cause of perinatal- and infantile-onset hypophosphatasia, Asfotase alfa provides long-term enzyme replacement therapy

Continue Reading

AZ initiate trials for using diabetes drug in kidney disease and heart failure

AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga with the aim of exploring its potential beyond the drug’s approved diabetes indication. AZ have initiated two randomised, placebo-controlled Phase IIIb outcome trials assessing Forxiga in the management of chronic kidney disease and chronic heart failure, within participants with and without type-2 diabetes. The

Continue Reading